Rapport Therapeutics (RAPP) Shares Outstanding (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Shares Outstanding (Entity) of $47.8 million for Q1 2026, up 30.99% year-over-year from $36.5 million in Q1 2025, and up 22.79% quarter-over-quarter from $38.9 million in Q4 2025.
Rapport Therapeutics (RAPP) Shares Outstanding (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Shares Outstanding (Entity) for 4 consecutive years, with $47.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 30.99% year-over-year to $47.8 million; the TTM figure through Mar 2026 stood at $47.8 million (up 30.99% YoY), while the FY2025 annual figure was $38.9 million, up 87.74% from the prior year.
- Shares Outstanding (Entity) grew to $47.8 million in Q1 2026 per RAPP's latest filing, from $38.9 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $47.8 million in Q1 2026 and bottomed at $1.4 million in Q2 2023.
- Historically, Shares Outstanding (Entity) has averaged $22.7 million across 4 years, with a median of $28.6 million in 2024.
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) soared 2291.84% — and 2025, when it rose 3.7%.
- Rapport Therapeutics' Shares Outstanding (Entity) stood at $1.5 million in 2023, then soared by 1277.25% to $20.7 million in 2024, then surged by 87.74% to $38.9 million in 2025, then climbed by 22.79% to $47.8 million in 2026.
- Business Quant data shows RAPP's Shares Outstanding (Entity) at $47.8 million in Q1 2026, $38.9 million in Q4 2025, and $37.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 47.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.47 Mn |
| Mar 31, 2026 | 47.24 Mn |
| Dec 31, 2025 | 38.93 Mn |
| Sep 30, 2025 | 37.93 Mn |
| Jun 30, 2025 | 35.44 Mn |
| Mar 31, 2025 | 35.27 Mn |
| Dec 31, 2024 | 20.74 Mn |
| Sep 30, 2024 | 34.86 Mn |
| Jun 30, 2024 | 10.67 Mn |
| Mar 31, 2024 | 2.05 Mn |
| Dec 31, 2023 | 1.51 Mn |
| Sep 30, 2023 | 1.53 Mn |
| Jun 30, 2023 | 1.44 Mn |